On January 27, 2022 Chimeric Therapeutics Ltd (ASX:CHM) reported that it has been issued a patent from the Unites States Patent and Trademark Office covering certain applications of chimeric antigen receptor (CAR) technology using chlorotoxin (CLTX), including Chimeric’s clinical-stage CAR T asset CHM 1101 and preclinical-stage CAR NK asset CHM 1301 (Press release, Chimeric Therapeutics, JAN 27, 2022, https://chimerictherapeutics.com/wp-content/uploads/2022/01/CHM-Receives-US-Patent-covering-CLTX-CAT-Technology.pdf [SID1234607406]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The patent has been granted under patent number US 11,230,577 B2 and entitled ‘Chimeric antigen receptors containing a chlorotoxin domain’.
Chimeric Therapeutics holds the exclusive worldwide licence to develop and commercialise US 11,230,577 B2 and related patent applications filed in other global territories.
Continued IP portfolio momentum
Chimeric Therapeutics CEO and managing director Jennifer Chow said: "We are delighted to have patent protection granted for CLTX CAR therapies in the United States, the single largest global market for biopharmaceutical products.
"The granting of this key US patent continues the momentum for the intellectual property portfolio underpinning our CLTX CAR pipeline assets, following the recent patent grant in Europe in September."
CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed by scientists at the City of Hope Medical Centre in California for the treatment of patients with solid tumours.It is currently being studied in a phase 1 clinical trial in recurrent/ progressive glioblastoma.
A second CLTX CAR T phase 1 clinical trial is planned to begin in 2022 in additional solid tumours.
CHM 2101 (CDH17 CAR T) is a novel, third-generation CDH17 CAR T invented at the University of Pennsylvania. CHM 2101 is in preclinical development with a planned phase 1 clinical trial in 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.